Current status of sorafenib in the treatment of advanced liver cancer
10.3760/cma.j.issn.1673-4904.2017.08.025
- VernacularTitle:索拉非尼治疗中晚期肝癌的现状
- Author:
Zhengzheng WANG
;
Kai WANG
;
Jinxue ZHOU
;
Qingjun LI
;
Xiangyu ZHAN
;
Feng HAN
- Keywords:
Sorafenib;
Liver cancer;
Molecular mechanism;
Therapeutic evaluation
- From:
Chinese Journal of Postgraduates of Medicine
2017;40(8):761-764
- CountryChina
- Language:Chinese
-
Abstract:
Sorafenib is the only molecular targeted drug therapy for advanced liver cancer recommended by the European Association for the study of liver diseases (EASL), American Association for the study of liver diseases (AASLD) and the United States Food and Drug Administration (FDA). As a multi kinase inhibitors, sorafenib can inhibit multiple signal transduction pathways of tumor cell proliferation and angiogenesis and obviously prolong the late stage of disease progression time and overall survival in patients with hepatocellular carcinoma (HCC). Criteria for evaluation of the efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) is increasingly perfect. The author gives a brief overview of the molecular mechanism, efficacy and safety and efficacy evaluation criteria of sorafenib in the treatment of advanced liver cancer.
